Panel Discussion: Embedding Liquid Biopsy Infrastructure to De-Risk LBx/CDx Strategy & Enable Scalable Precision Medicine Execution

• Align assay performance and pre-analytical validation with regulatory-grade CDx requirements to ensure sample integrity, analytical robustness and global approval confidence
• Standardize collection, handling and laboratory workflows across trial networks to reduce variability, protect data quality and enable reproducible, scalable execution
• Integrate translational biomarker strategy with operational laboratory oversight to bridge early molecular insight with decision-grade, clinically deployable implementation

Speakers:

Feng Hong

Senior Director & Head, Clinical Laboratory Operations, Precision Medicine

Regeneron

Angela Silvestro

Director, Companion Diagnostics

GSK

Jon Beer

Senior Director, Precision Medicine

Bristol Myers Squibb

Zheng Feng

Head, Clinical Genomics, Clinical Measurement Sciences

EMD Serono, An affiliate of Merck KGaA, Darmstadt, Germany